MOH:NYE-Molina Healthcare Inc (USD)

EQUITY | Healthcare Plans | New York Stock Exchange

Last Closing

USD 329.65

Change

-8.04 (-2.38)%

Market Cap

USD 2.95B

Volume

1.01M

Analyst Target

USD 205.23
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Molina Healthcare Inc offers Medicaid-related solutions to meet the health care needs of low-income families and individuals, and to assist government agencies in administration of the Medicaid program.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-08 )

Largest Industry Peers for Healthcare Plans

Symbol Name Price(Change) Market Cap
UNH UnitedHealth Group Incorporate..

+9.44 (+1.53%)

USD 566.72B
ELV Elevance Health Inc

+2.77 (+0.66%)

USD 95.26B
CNC Centene Corp

+0.60 (+1.00%)

USD 30.37B
OSCR Oscar Health Inc

+0.26 (+1.92%)

USD 4.12B
NEUE NeueHealth Inc

-0.04 (-0.79%)

USD 0.05B
CI Cigna Corp

+23.29 (+7.28%)

N/A
CVS CVS Health Corp

+0.27 (+0.49%)

N/A
HUM Humana Inc

-5.68 (-1.97%)

N/A

ETFs Containing MOH

ABCS Alpha Blue Capital US Sma.. 1.50 % 0.00 %

+0.29 (+0.96%)

USD 0.01B
RISN Inspire Tactical Balanced.. 1.20 % 0.00 %

+0.24 (+0.96%)

USD 0.09B
EQWM Invesco S&P MidCap Qualit.. 0.00 % 0.25 %

N/A

N/A
GREK Global X MSCI Greece ETF 0.00 % 0.59 %

-0.14 (0.96%)

USD 0.19B
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

+0.97 (+0.96%)

N/A
PXMV Invesco S&P MidCap Value .. 0.00 % 0.39 %

+0.88 (+0.96%)

N/A
FDHY Fidelity® High Yield Fac.. 0.00 % 0.45 %

+0.07 (+0.96%)

USD 0.35B
XMC:CA iShares S&P US Mid-Cap 0.00 % 0.16 %

+0.32 (+0.96%)

CAD 0.39B
XMH:CA iShares S&P US Mid-Cap CA.. 0.00 % 0.16 %

+0.25 (+0.96%)

CAD 0.26B
DMRM 0.00 % 0.45 %

N/A

N/A
IJH:AU iShares CoreS&P MidCap 40.. 0.00 % 0.00 %

+0.96 (+0.96%)

USD 0.32B
XMC-U:CA iShares S&P U.S. Mid-Cap .. 0.00 % 0.00 %

+0.32 (+0.96%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Healthcare Plans) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.18% 63% D 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.18% 63% D 14% F
Trailing 12 Months  
Capital Gain -38.63% 75% C 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.63% 75% C 12% F
Trailing 5 Years  
Capital Gain 74.17% 100% F 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.17% 100% F 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 22.55% 88% B+ 83% B
Dividend Return 22.55% 88% B+ 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.86% 38% F 42% F
Risk Adjusted Return 87.21% 100% F 93% A
Market Capitalization 2.95B 50% F 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Healthcare Plans) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.00 50% 53%
Price/Book Ratio 3.90 40% 24%
Price / Cash Flow Ratio 11.20 50% 36%
Price/Free Cash Flow Ratio 6.54 67% 65%
Management Effectiveness  
Return on Equity 26.45% 100% 90%
Return on Invested Capital 20.81% 100% 89%
Return on Assets 6.90% 83% 85%
Debt to Equity Ratio 51.72% 67% 61%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector